Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics Inc (NQ: RLMD )

18.50 -1.09 (-5.59%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,513
Open 19.38
Bid (Size) 18.42 (1)
Ask (Size) 18.56 (2)
Prev. Close 19.59
Today's Range 18.19 - 19.38
52wk Range 16.23 - 39.66
Shares Outstanding 17,472,986
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading. 
Via Benzinga
Relmada Therapeutics Earnings Preview
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga

Performance

YTD
-21.86%
-21.86%
1 Month
-27.53%
-27.53%
3 Month
+1.23%
+1.23%
6 Month
-4.66%
-4.66%
1 Year
-51.49%
-51.49%

More News

Read More
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Via Benzinga
Here's Why Relmada Therapeutics Shares Are Rising
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Earnings Scheduled For November 11, 2021
Via Benzinga
Earnings Scheduled For August 10, 2021
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Via Benzinga
Exposures COVID-19
Earnings Scheduled For March 23, 2022
Via Benzinga
Relmada Therapeutics's Earnings Outlook
Via Benzinga
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Via Benzinga
Exposures COVID-19 Product Safety
Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
Via Benzinga
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Via FinancialNewsMedia
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2021
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Relmada Sees Price Target Bump From Leerink, Truist After Positive Data From MDD Candidate
Via Benzinga
Here's Why Relmada Therapeutics Stock Popped Today
Via The Motley Fool
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.